Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Jul;18(3):275-9.
doi: 10.1080/08998280.2005.11928082.

Rasburicase (Elitek): a novel agent for tumor lysis syndrome

Sis Ueng  1
Affiliations

Rasburicase (Elitek): a novel agent for tumor lysis syndrome

Sis Ueng. Proc (Bayl Univ Med Cent). 2005 Jul.

Abstract

The overall incidence of tumor lysis syndrome in adults is not well defined, and its occurrence can be unpredictable. Several strategies are available for the prevention and treatment of tumor lysis syndrome, with rasburicase being the most recent. Rasburicase is a recombinant urate oxidase enzyme approved for use by the Food and Drug Administration in patients who are at risk of developing tumor lysis syndrome or for the management of elevated uric acid levels. Clinical trials have demonstrated rasburicase to be effective in both the pediatric and adult populations, although the drug is currently indicated only for use in the pediatric population. Adverse effects associated with rasburicase can be significant, ranging from anaphylactic reactions to methemoglobinemia. To ensure accuracy of uric acid test results, special laboratory handling procedures must be followed while patients receive rasburicase. Compared with allopurinol and intravenous sodium bicarbonate, rasburicase is costly, and therefore judicious use of the medication is warranted.

PubMed Disclaimer

Figures

Figure
Figure
Draft physician orders for rasburicase.
See this image and copyright information in PMC

References

    1. Warrell RP. Metabolic emergencies. In: Devita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. pp. 2633–2644.
    1. Navolanic PM, Pui CH, Larson RA, Bishop MR, Pearce TE, Cairo MS, Goldman SC, Jeha SC, Shanholtz CB, Leonard JP, McCubrey JA. Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a meeting report, Dallas, Texas, January 2002. Leukemia. 2003;17:499–514. - PubMed
    1. Cairo MS. Prevention and treatment of hyperuricemia in hematological malignancies. Clin Lymphoma. 2002;3(Suppl 1):26–31. - PubMed
    1. Sanofi-Synthelabo . Elitek(™) (Rasburicase) Prescribing Information [package insert] New York: Sanofi-Synthelabo; 2002. Available at http://www.sanofi-synthelabous.com/products/pi_elitek/pi_elitek.html; accessed April 12, 2005.
    1. Ribeiro RC, Pui CH. Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies. Clin Lymphoma. 2003;3:225–232. - PubMed

LinkOut - more resources